Hyloris to Report 2021 Half-Year Results on 4 August 2021
27 Luglio 2021 - 07:00AM
Liège, Belgium – 27 July
2021 – Hyloris
Pharmaceuticals SA (Euronext Brussels:
HYL), a specialty biopharma company
committed to addressing unmet medical needs through reinventing
existing medications, today announces that it will host a
conference call and audio webcast on Wednesday, 4 August 2021 at
3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial
results and to provide a business update. The presentation will be
followed by a live Q&A session.
The webcast may be accessed on the Events page
of the company’s website or by clicking here. To participate in the
Q&A session of the conference call, please dial one of the
following numbers, ten minutes prior to the start of the live
webcast:
Belgium
+32 2 79 338
47France
+33 1 70 700 781Netherlands
+ 31
20 795 6614United Kingdom
+44 2071 928 338United States
+1 646 741 3167
Confirmation code 2687826
Following the call, a replay of the webcast will
be available on the events page of the Hyloris website.
About Hyloris
Pharmaceuticals
Hyloris is a specialty biopharma company focused
on innovating, reinventing, and optimising existing medications to
address important healthcare needs and deliver relevant
improvements for patients, healthcare professionals and payors.
Hyloris has built a broad, patented portfolio of 13 reformulated
and repurposed value-added medicines that have the potential to
offer significant advantages over available alternatives. Two
products are currently commercialised with partners: Sotalol IV for
the treatment of atrial fibrillation, and Maxigesic® IV, a
non-opioid post-operative pain treatment. The Company’s development
strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway,
which is specifically designed for pharmaceuticals for which safety
and efficacy of the molecule have already been established. This
pathway can reduce the clinical burden required to bring a product
to market, and significantly shorten the development timelines and
reduce costs and risks. Hyloris is based in Liège, Belgium. For
more information, visit www.hyloris.com and follow-us on
LinkedIn.
For more information, please
contact Hyloris
Pharmaceuticals:
Marieke VermeerschVP Investor Relations and
Corporate CommunicationsM: +32 (0)479 490
603marieke.vermeersch@hyloris.com
Disclaimer and forward-looking
statementsHyloris means “high yield, lower risk”, which
relates to the 505(b)(2) regulatory pathway for product approval on
which the Issuer focuses, but in no way relates or applies to an
investment in the Shares.Certain statements in this press release
are “forward-looking statements.” These forward-looking statements
can be identified using forward-looking terminology, including the
words "believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. These statements relate to future events or the Company’s
future financial performance and involve known and unknown risks,
uncertainties, and other factors, many of which are beyond the
Company’s control, that may cause the actual results, levels of
activity, performance or achievements of the Company or its
industry to be materially different from those expressed or implied
by any forward-looking statements. The Company undertakes no
obligation to publicly update or revise forward-looking statements,
except as may be required by law.
- 210727 Hyloris Press Release_Notice of HY21
Results_ENG_Final
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hyloris Pharmaceuticals (EU:HYL)
Storico
Da Mar 2023 a Mar 2024